The Joint Programme continued to play a leading role in strategically convening scientists, communities and multisectoral stakeholders, including through international fora and expert reports, to ensure the most up-to date evidence and innovations for HIV testing, treatment, care, support integrated services and develop normative, strategic and implementation guidance.
Supporting countries in aligning their national policies and programmes with evidence-based guidelines remained a central focus of the Joint Programme’s work in 2022. The Joint Programme’s work in promoting the adoption and implementation of global guidance for the best HIV treatment to be accessible to all who need it has achieved concrete results. More than 95% of countries now implement a “treat all” approach.
| Joint Programme specific outputs for 2022- 2023 |
|---|
| 2.1 Update, disseminate and promote implementation of updated technical guidance that harness technical and operational innovations to optimize access to and uptake of HIV testing, treatment, care, support and integrated services, including those that address comorbidities and coinfections, with a focus on tuberculosis (TB), viral hepatitis C, cervical cancer, and infections linked to high mortality (advanced HIV disease) |
| 2.2 Provide policy, advocacy and technical support to countries to update/adopt and implement national policies and service delivery programmes aligned with the new global guidance for effective scaling up of quality HIV testing, treatment, care and integrated services including those for comorbidities and coinfections. |